生物股份(600201.SH):子公司取得新獸藥註冊證書
格隆匯9月5日丨生物股份(600201.SH)公佈,經國家農業農村部審查,批准公司全資子公司金宇保靈生物藥品有限公司自主開發的布魯氏菌病活疫苗(Rev.1株)為新獸藥,並核發了《新獸藥註冊證書》。布魯氏菌病是由布魯氏菌引起的世界範圍分佈的人畜共患慢性傳染病。目前,我國布魯氏菌病流行的主要菌種為羊種布魯氏菌,陽性羊為布魯菌病主要傳染源,通過疫苗免疫是控制羊布魯氏菌病的有效方式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.